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ABSTRACT
This review addresses pitfalls of clinical trials to evaluate new approaches for prevention or treatment of graft-
versus-host disease. Determination of end points poses a difficult challenge in the design of clinical trials, and
examples from previous studies are used to illustrate some of the pitfalls. Also discussed is the need for a new
conceptual approach for evaluation of graft-versus-host disease after nonmyeloablative conditioning regimens,
because the donor antirecipient alloimmune reaction is the primary mechanism of benefit with this type of treatment.
Finally, investigators should be aware of regulatory and socioeconomic pitfalls that apply to all clinical trials.
© 2006 American Society for Blood and Marrow Transplantation
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oNTRODUCTION
This review of pitfalls in clinical trials for prevention
r treatment of acute graft-versus-host disease (GVHD)
eﬂects the authors’ personal experience and does not
epresent a global survey of the literature. The merits of
ifferent end points for prevention and treatment studies
re evaluated, and some of the limitations of phase II
tudies are outlined. The increased reliance on immune
eactions to control malignant disease after nonmyelo-
blative conditioning regimens leads to suggestions for a
ew conceptual approach to the evaluation of GVHD.
inally, some of the regulatory and socioeconomic pit-
alls that apply to all clinical trial are discussed.
ND POINTS FOR PHASE III PREVENTION STUDIES
urvival as an End Point
Survival has been a difﬁcult end point to achieve in
VHD prevention studies. Increased survival related
his research was supported by grants CA18029 from the Public Health
ervice, Department of Health and Human Services. Clinical trials
omparing cyclosporine and tacrolimus for prevention of acute graft-
ersus-host disease were supported in part by grants from Fujisawatealthcare.
B&MTo an intervention to prevent GVHD can be demon-
trated only if the risk of GVHD in the study popu-
ation is very high and the risks of non-GVHD com-
lications are very low and balanced between arms. In
ddition, the intervention must have a large beneﬁcial
ffect, with no increased risk of fatal adverse effects
hat would offset the beneﬁts of preventing GVHD.
hroughout the history of hematopoietic cell trans-
lantation (HCT), very few studies have met all of
hese criteria, and for this reason, very few studies
ave demonstrated improved survival through inter-
entions designed to prevent GVHD.
Table 1 presents hypothetic data to illustrate the
ifﬁculty of demonstrating an improvement in sur-
ival related to more effective prevention of acute
VHD. After HCT with unrelated donors in the late
980s and early 1990s, the expected frequency of
rade IV GVHD was approximately 10%, and for
hese patients, the risk of nonrelapse mortality ap-
roaches 100%. The expected frequency of grade III
VHD was approximately 30%, and for these pa-
ients, the nonrelapse mortality is approximately 50%.
rade II GVHD has little detectable effect on non-
elapse mortality after HCT. The expected frequency
f grades 0 to II GVHD after unrelated transplanta-
ion was approximately 60%, and the combined non-
31
r
a
a
a
a
w
p
f
G
t
p
2
t
r
G
b
f
c
u
t
o
i
m
G
o
s
b
b
u
b
G
r
G
a
a
p
o
m
c
o
E
P
s
t
d
p
h
[
T
I
T
I
i
p
s
t
k
G
u
g
g
o
i
r
f
c
c
u
d
a
d
a
H
f
c
v
a
w
s
p
b
w
b
t
m
a
T
N
G
P. J. Martin and R. A. Nash
3elapse mortality at 1 to 2 years for these patients was
pproximately 25%. Under these conditions, the over-
ll expected nonrelapse mortality in the control arm of
study to prevent GVHD would be estimated at
pproximately 40%.
A reasonably effective therapy to prevent GVHD
ould be expected to prevent grade IV GVHD and
ossibly decrease the incidence of grade III GVHD
rom 30% to 15%. Given the relationships between
VHD grade and survival described above, however,
his striking reduction in GVHD risk would be ex-
ected to decrease nonrelapse mortality from 40% to
9% (Table 1). A randomized prospective clinical trial
o detect the difference between 40% and 29% would
equire enrollment of at least 600 patients.
VHD as an End Point
Survival is difﬁcult end point for GVHD studies,
ut the measurement of GVHD itself as an end point
or prevention studies also has pitfalls. Qualitative
omponents of the diagnosis are very difﬁcult to doc-
ment. In most cases, clinicians can conﬁdently dis-
inguish rash caused by GVHD from rash related to
ther causes, but the case report forms used for clin-
cal trials cannot easily capture the qualitative ele-
ents that led to the distinction. The assessment of
VHD severity is often confounded by complications
ther than GVHD. For example, both GVHD and
inusoidal obstruction syndrome cause hyperbiliru-
inemia, and the distinction between the two must be
ased on concomitant ﬁndings such as ascites, right
pper quadrant tenderness, or rash. Hyperbiliru-
inemia in the absence of rash is usually not related to
VHD, but hyperbilirubinemia presenting concur-
ently with rash is usually interpreted as related to
VHD. The principle of parsimony does not always
able 1. Hypothetical Effect of Graft-versus-Host Disease on
onrelapse Mortality
Standard Prophylaxis
GVHD Grade
Expected
Frequency
Risk of
NRM
Expected
NRM
0–II 0.6 0.25 0.15
III 0.30 0.5 0.15
IV 0.10 1.0 0.10
Total 0.40
Experimental Prophylaxis
GVHD Grade
Expected
Frequency
Risk of
NRM
Expected
NRM
0–II 0.85 0.25 0.21
III 0.15 0.5 0.08
IV 0 1.0 0
Total 0.29
VHD indicates graft-versus-host disease, NRM, nonrelapse mor-
tality.pply, however, and patients can have both GVHD r
2nd other complications simultaneously. Finally, the
eak severity of GVHD reﬂects not only the efﬁcacy
f the prophylaxis, but also the efﬁcacy of later treat-
ent. In a prevention study, the effects of treatment
an blunt differences between the arms that would
therwise be much more apparent.
xamples from Previous Phase III
revention Studies
Two important prospective trials [1,2] illustrate
ome of the problems associated with end-point de-
ermination related to GVHD. Both studies were con-
ucted to compare tacrolimus and cyclosporine for
revention of acute GVHD. In one study [1], patients
ad HLA-matched sibling donors, and in the other
2], patients had HLA-matched unrelated donors.
hese multicenter studies are among the largest phase
II randomized GVHD prevention trials ever done.
he primary end point for each study was grade II to
V GVHD, and both had an open-label design.
A variety of methods were used to assess GVHD
n these studies. One was clinical assessment by the
rimary investigators. Because this was an open-label
tudy, the primary investigators knew whether pa-
ients were taking cyclosporine or tacrolimus, and this
nowledge could have inﬂuenced their assessment of
VHD. A computer algorithm was also used to eval-
ate all-cause morbidity involving the skin, liver, and
astrointestinal tract. This algorithm did not distin-
uish between morbidity related to GVHD versus
ther causes. A further, and perhaps more telling,
ndication of whether a patient had GVHD was ste-
oid administration. In addition to receiving steroids
or treatment of GVHD, however, some patients re-
eived steroids as substitute prophylaxis when the cal-
ineurin inhibitor could not be given. The study of
nrelated HCT in which this end point was analyzed
id not distinguish among the different reasons for
dministration of steroids.
A 3-member end-point evaluation committee in-
ependently assessed the acute GVHD end point for
ll patients participating in the study of unrelated
CT. The committee members were expert clinicians
rom institutions that were not participants in the
linical trial. Committee members retrospectively re-
iewed abstracts and ﬂow sheets of the clinical data
nd pertinent supportive documentation, but they
ere blinded to the study drug assignment. Biopsy
pecimens were available for review if subsequent
athologic evaluation was necessary. Flow sheets used
y the committee described clinical manifestations at
eekly intervals and summarized laboratory results,
iopsy reports, and complications other than GVHD
hat might confound the diagnosis. Compliance with
ethotrexate administration was recorded. Compli-
nce with administration of the study drug was also
eported, together with information indicating blood
l
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Pitfalls in Design of Clinical Trials
Bevels of the study drug coded in a manner that did not
isclose the identity of the study drug. Information
bout treatment of acute GVHD was not provided to
he committee.
In the study of patients with HLA-matched sibling
onors [1], the incidence of GVHD determined by
he investigator was 26% in the tacrolimus arm and
1% in the cyclosporine arm (Table 2). The computer
lgorithm reﬂecting morbidity from all causes had
uch higher estimates, 80% and 85%, respectively. In
he study with unrelated donors [2], investigator as-
essment again showed a statistically signiﬁcant differ-
nce between arms (Table 3). The frequency of ste-
oid administration was higher in both arms, in part
ecause of substitute prophylaxis when the calcineurin
nhibitor could not be given. The committee under-
stimated the incidence of GVHD compared with
eports by the investigators, possibly because the re-
iewers did not have information about GVHD treat-
ent. Differences in the estimates of GVHD inci-
ence by the various methods used in these two
tudies are striking.
In the study with unrelated donors, data from the
rimary investigator assessments (Table 4) showed an
nverse correlation between the number of patients
nrolled at each site and the percentage-point differ-
nce between the two arms. At the largest center, the
ifference between the two arms was only 6%. In
enters B, C, D, E, and F, the differences between
rms were in the vicinity of 21% to 26%. In the
mallest centers, enrolling only 10 patients in one
enter and 7 patients from 3 other centers, the differ-
nces between arms were 50% to 60%. Smaller cen-
ers with a limited number of physicians could have
ad strong biases about the efﬁcacy of tacrolimus
ompared with cyclosporine, whereas in larger cen-
ers, the care is spread across many more individuals
ho might not share those same biases.
able 2. Incidence of Grades II to IV Graft-versus-Host Disease
Method of
Evaluation
Tacrolimus Cyclosporine
PTotal GVHD (%) Total GVHD (%)
nvestigator* 165 43 (26) 164 67 (41) .01
omputer† 165 131 (79) 164 139 (85) .20
VHD indicates graft-versus-host disease.
Ratanatharathorn et al [1].
Nash et al., unpublished data.
able 3. Incidence of Grades II to IV Graft-versus-Host Disease
Method of Evaluation
Tacrolimus,
N (%)
Cyclosporine,
N (%) P
nvestigator [2] 46 (51) 63 (70) .01
teroid administration 59 (66) 73 (81) .02n
ommittee 18 (20) 29 (32) .06
B&MTThese observations raise the concern that the di-
gnosis of GVHD was inﬂuenced by the awareness of
hether the patient was taking cyclosporine or tacroli-
us. In these studies, it is unlikely that GVHD was
nderdiagnosed among patients who received tacroli-
us. If GVHD evolved to the point where it needed
o be treated, it should have been diagnosed and
reated in the interest of good patient care. It is pos-
ible, however, that GVHDwas overdiagnosed among
atients who received cyclosporine, particularly if cli-
icians considered cyclosporine to be less effective for
reventing GVHD. In this case, the increased suspi-
ion of GVHD would lead to earlier treatment than
ould have been the case for an otherwise identical
atient who had received tacrolimus. Patients who
eceived cyclosporine and early treatment were la-
eled as having GVHD for a condition that could
onceivably have resolved spontaneously if treatment
ad been delayed, as might have been the case for
ome of the patients in the tacrolimus arm. This con-
ern, however, would not apply for the committee
valuation of GVHD in the study of unrelated HCT,
ecause the committee did not have information
bout GVHD treatment.
Another way of evaluating outcomes in GVHD
revention trials is to assess overall morbidity across
ime (Nash et al., unpublished observations). Results
rom the unrelated transplantation trial [2] showed
hat the burden of morbidity among patients with
rades III to IV GVHD was statistically higher than
mong those with grades 0 to II GVHD. It was very
ifﬁcult to demonstrate that the burden of morbidity
mong patients with II to IV GVHD was higher than
mong those with grades 0 to I GVHD. The study
rms were then compared in proportional odds mod-
ls to determine whether there was any difference
cross time in the severity of rash, the degree of
yperbilirubinemia, or the severity of gut symptoms.
wo different methods were used to calculate an over-
ll score; one method followed the standard algorithm
or grading GVHD and the other assigned less weight
o the severity of gut symptoms. The results showed
able 4. Inconsistent Results Between Centers
Sites(s) No. of Patients
Difference between
Arms, %
A 75 6
B 25 21
C 20 20
D 17 19
E 13 26
F 13 26
G 10 60
HIJ 7 50
ased on graft-versus-host disease grades assigned by investiga-
tors (Nash et al., unpublished data).o signiﬁcant differences between the study arms, but
33
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3he trends suggested a lower overall burden of mor-
idity in the skin and liver among patients in the
acrolimus arm. Almost all patients had gut symptoms
aused by the conditioning regimen, and this ﬁnding
ay explain the absence of differences in gut morbid-
ty between arms.
Recent studies have shown improvements in the
onsistency of GVHD grading by different methods.
eisdorf et al. [3] showed excellent consistency of
VHD grading when an evaluation committee was
nformed of the treatment decisions that were made
y the clinicians at the bedside. The sophistication of
he computer algorithm was also improved, probably
y taking into account treatment and not simply eval-
ating morbidity, so there was close agreement with
esults of the panel review. The inclusion of treatment
ecisions in the committee evaluation and the com-
uter algorithm, however, introduces an unavoidable
ubjective component in the grading that could be
ffected by the bias of investigators who are aware of
he study arm assignments in open-label studies.
ND POINTS FOR PHASE III TREATMENT STUDIES
Compared with the large number of studies assess-
ng GVHD prophylaxis, relatively few studies of
VHD treatment have been reported, in part because
f the difﬁculty and complexity of evaluating the re-
ults of GVHD treatment. Minimal criteria for im-
rovement or progression of GVHD in each organ
ust be deﬁned, and few published studies have given
xplicit consideration to the effects of other posttrans-
lantation complications involving the gut or liver.
nd-point deﬁnition is also a problem, and the bound-
ries between GVHD grades are arbitrary to some ex-
ent. The timing of assessments can be crucial, because
VHD can show a waxing and waning course. Further-
ore, an individual organ such as the skin or gut can
emonstrate regional differences in response to treat-
ent, and improvement of GVHD in one organ can
e accompanied by worsening in another.
Competing risks and the complexity of add-on
esigns can cause other pitfalls. At any given time
oint, some patients may have already received addi-
ional therapy because of lack of satisfactory response
o initial treatment, and others may have died. If the
rimary end point is GVHD severity across time, the
nalysis must account for patients who have died or
eturned home. In studies with an add-on design, the
nderlying standard treatment given to both arms can
lunt any differences between arms.
Another difﬁculty is assessment of improvement.
or example, the outcome for a patient could be clas-
iﬁed as improvement because the GVHD has changed
rom grade III to grade II severity, but this change in
rade may have been diagnosed on the basis of a i
4ecrease in the total serum bilirubin concentration
rom 3.1 to 2.9 mg/dL. To circumvent problems of
his type, we have used a more sophisticated algorithm
or assessing outcomes after treatment of acute
VHD [4]. The deﬁnition of skin improvement, for
xample, required a more than 25 percentage-point
eduction in the total body surface affected by rash.
rogression was the opposite, a greater than 25 per-
entage-point increase, and no change was the ab-
ence of either improvement or progression. We val-
dated the deﬁnitions by showing that patients who
ad complete response, as we deﬁned it at the time,
ad a lower incidence of nonrelapse mortality than
hose who had a partial response or mixed response
improvement in one organ but worsening in an-
ther). The patients with the worst outcome had pro-
ression or no change.
We assessed response with this algorithm in a
ouble-blind prospective clinical trial of a CD5-spe-
iﬁc immunotoxin plus steroids compared with ste-
oids alone for treatment of GVHD [5]. We collected
ata weekly and categorized patients as having a par-
ial or complete response. The results showed that
VHD improved within the ﬁrst few weeks in most
atients. The main end point of interest was the pro-
ortion of patients who had complete responses. There
as a 2- to 4-week advantage in time to resolution of
VHD in the patients who received the immuno-
oxin, but the end results at 6 weeks were similar in the
wo arms. This study illustrates the problem of blunt-
ng, in that steroid treatment alone produced a high
omplete response rate, making it difﬁcult to demon-
trate any improvement resulting from additional
reatment.
VOIDING PITFALL IN PHASE III STUDIES
Several methods can be used to circumvent the
itfalls of GVHD trials. Blinding can be an effective
ay to lessen the impact of investigator subjectivity,
ut blinding can be difﬁcult to carry out. Blinding
as suggested for the trials comparing tacrolimus
nd cyclosporine, but such a design would have
equired the collaboration of two competing phar-
aceutical companies. A blinded design would
ikely have increased the number of capsules that
atients would have to take, and it would have been
ecessary to normalize the reporting of drug levels
o preserve the blind while allowing physicians to
se this information in the clinical treatment of
atients.
Another crucial element is prespeciﬁcation of the
nd points and the timing of assessments. The pri-
ary end point has to be selected to demonstrate
linical beneﬁt, either by prolonging life or by reduc-
ng GVHD-related symptoms such as rash or nausea
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Pitfalls in Design of Clinical Trials
Bnd vomiting. Clinical beneﬁt is more difﬁcult to deﬁne
or hepatic GVHD, because hyperbilirubinemia usually
oes not cause symptoms, although the degree of hyper-
ilirubinemia could be used as a surrogate end point that
s strongly correlated with nonrelapse mortality [6].
Adequate statistical power for the primary end
oint is essential. To that end, a phase II study or
obust historic data are needed to deﬁne expectations
or the study arm and the control arm in a phase III
linical trial, so that the power analysis is informed by
ata and not by mere guesses. Balancing risk factors
etween arms is also important, as demonstrated by
he trial comparing cyclosporine and tacrolimus
mong patients with sibling donors [1,7].
IMITATIONS OF PHASE II STUDIES
Awareness of problems in GVHD assessment
eads to a critical examination of phase II studies in
hich there is lack of blinding and a poorly deﬁned
rimary end point. In many phase II studies the
iming of assessments and the statistical analysis are
ot prespeciﬁed. The eligibility criteria for a clini-
al trial reﬂect a balance between several conﬂicting
nterests that can drastically inﬂuence the results.
he investigator’s desire to demonstrate success
eads to tight eligibility criteria that exclude patients
ho are at high risk of complications, whereas the
esire to complete the study may lead to a relaxed
et of eligibility criteria, potentially making it more
ifﬁcult to demonstrate success. In the provider
ole, the investigator is motivated by a desire to help
atients and may encourage enrollment out of hope
hat the study intervention will be effective. Finding
he appropriate balance among these interests can
e extremely difﬁcult.
Patients make their own assessments of beneﬁts
nd risks when deciding to participate in a clinical
rial. For example, in a recent study to test the
fﬁcacy of a CD25 immunotoxin to prevent acute
VHD, the number of patients who declined to
articipate in a study was larger than the number
ho enrolled in the study [8]. The patients who
nrolled had higher-risk disease and were signiﬁ-
antly older than those who declined to participate.
uch selection biases may go unnoticed unless ef-
orts are made to record the characteristics of pa-
ients who decline to participate in clinical trials.
VALUATION OF GVHD AFTER NONMYELOABLATIVE
ONDITIONING REGIMENS
Regimen-related toxicity can be decreased by the
se of nonmyeloablative conditioning regimens, and
here is an increasing reliance on immunologic effects
f donor cells for efﬁcacy in HCT. A complete rever- a
B&MTal of priorities in regard to GVHD may occur for a
atient who has had recurrent or progressive malig-
ancy, and this change will affect GVHD analysis. As
result, there is an increased willingness to accept
ome GVHD as a necessary cost of treatment.
Consistency remains, however, in the desire to
void severe adverse consequences related either to
cute or chronic GVHD–“too much” GVHD [9]. A
ypical patient with acute myeloid leukemia may un-
ergo extended hospitalization of 60 to 90 days in
given year in the course of treatment. If this length
f hospitalization would be considered tolerable for
anagement of acute leukemia, it may also be consid-
red tolerable for a patient with GVHD. On the other
and, persistent or signiﬁcant disability or incapacity
elated to bronchiolitis obliterans, contractures, or
orneal disease might not be considered acceptable as
he price of overcoming leukemia. By the same token,
ecurrent life-threatening infections requiring hospi-
alization or causing death related to GVHD or im-
unosuppressive treatment are obviously situations
e want to avoid. Most would agree that these out-
omes exemplify too much GVHD. Perhaps this judg-
ent could be used as an end point for clinical trails,
esting the level of success in allowing enough immu-
ologic activity to control the malignancy, while at the
ame time avoiding the consequences of too much
VHD.
EGULATORY AND SOCIOECONOMIC PITFALLS
Awareness of regulations related to the conduct of
linical trials is vitally important for investigators.
ormal training programs are now becoming available
o familiarize academic clinicians with the Code of
ederal Regulations, the International Conference on
armonization guidelines, and Food and Drug Ad-
inistration Good Clinical Practice guidelines.
Concerns about academic credit can impede the
evelopment of multicenter clinical trials. When it
omes to promotions, the number of publications is
onsidered together with an interpretation regarding
he role of the candidate, often based on the position
ithin the list of authors. In smaller centers that can-
ot contribute large numbers of patients to a clinical
rial, the contribution will most likely result in listing
s a middle author, which will have less impact than
isting as ﬁrst, second, or last author.
As an intrinsic part of the scientiﬁc method, in-
estigators do not have completely neutral views when
clinical trial is designed. Belief in the potential su-
eriority of a new treatment underpins the design of
ny clinical trial, as expressed in the statistical consid-
rations that specify the quantitative benchmarks of
uccess to be used at the end of the trial. Regardless of
ny expectations or hopes of success at the beginning
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3f a clinical trial, the investigator must step back to
ake disinterested and unbiased judgments at the end
f the trial, even though it would be more rewarding
o publish positive results than negative results.
Financial entanglements can pose difﬁcult prob-
ems for academic investigators. Some believe that
cademic investigators should have a completely neu-
ral judicial role, in which any funding or any beneﬁt
oming directly from someone who has an advocacy
ole in the advancement of a product must be avoided.
edical journals now deal with this problem by pro-
iding disclosure statements, but these statements
enerally do not provide enough information to de-
ermine the extent to which objectivity might have
een compromised by any ﬁnancial support or other
eneﬁts.
Differences between corporate culture and aca-
emic culture can cause unanticipated problems. Cor-
orate success is measured by proﬁt, while academic
uccess is measured by publication, and ﬁnding com-
on ground can be very difﬁcult. For example, a
ecision by a pharmaceutical company to close a clin-
cal trial prematurely for ﬁnancial reasons would rep-
esent a complete loss for an academic investigator
ho could not publish the results of the study. Like-
ise, the two cultures might conﬂict when it comes to
ublication of negative results that might be harmful
o the company but beneﬁcial to the academic inves-
igator and the public.
ONCLUSIONS
The complexity of GVHD poses many challenges
n the design of clinical trials to evaluate new ap-
roaches for prevention or treatment of GVHD.
wareness of potential pitfalls leads to recognition of
he necessity for clearly deﬁned and realistic end
oints that reﬂect genuine clinical beneﬁt. Clinical
nvestigators must balance the demands of regulatory
gencies, corporate interests, and academic advance-
ent with their mission to provide patient care. The
6iases inherent in a scientiﬁc hypothesis-generating,
ypothesis-testing mind-set at the beginning of a clin-
cal trial must be replaced by scrupulously protected
bjectivity when the results are judged at the end of a
linical trial.
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